AP-23573

Known as: AP23573 
A small molecule and non-prodrug analog of rapamycin with potent antitumor activity. AP23573 binds to and inhibits the mammalian target of rapamycin… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2015
024620032015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669… (More)
  • table 1
  • table 2
Is this relevant?
2010
2010
BACKGROUND Mammalian target of rapamycin (mTOR) inhibitors may have efficacy as an intervention for advanced malignancies. Oral… (More)
Is this relevant?
2010
2010
BACKGROUND The additive cytotoxicity in vitro prompted a clinical study evaluating the non-prodrug rapamycin analogue… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
PURPOSE This was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE This phase I trial was conducted to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Metastatic sarcomas are commonly resistant to chemotherapy. The serine/threonine kinase, mammalian target of rapamycin (mTOR), is… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Lung cancer is a genetically heterogeneous disease characterized by the acquisition of somatic mutations in numerous protein… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
9505 Background: AP23573 is an mTOR inhibitor that has shown anti-tumor activity in phase 1 clinical trials, particularly in… (More)
Is this relevant?
2006
2006
ARIAD Pharmaceuticals Inc is developing intravenous and oral formulations of AP-23573, a rapamycin analog and inhibitor of mTOR… (More)
Is this relevant?